Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
about
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentGenetics and biology of pancreatic ductal adenocarcinomaK-Ras protein as a drug targetKRAS as a Therapeutic TargetRAS isoforms and mutations in cancer at a glanceRAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?Individual S-acylated cysteines differentially contribute to H-Ras endomembrane trafficking and acylation/deacylation cycles.Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis.Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategyIsoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms.Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateDivergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases.A New View of Ras Isoforms in Cancers.KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4AMcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding.Squamous Cell Cancers: A Unified Perspective on Biology and GeneticsHow to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation.Correlated S-palmitoylation profiling of Snail-induced epithelial to mesenchymal transitionClick-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation.Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.Targeting RAS-mutant cancers: is ERK the key?Metabolic Dependencies in RAS-Driven Cancers.Direct Modulation of Small GTPase Activity and Function.The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.The G protein-coupled receptor GPR31 promotes membrane association of KRAS.K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?The renewed battle against RAS-mutant cancers.Calmodulin and PI3K Signaling in KRAS Cancers.Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.The role of wild type RAS isoforms in cancer.The interplay between cell signalling and the mevalonate pathway in cancer.The Nogo-B receptor promotes Ras plasma membrane localization and activationTargeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.Drugging RAS: Know the enemy.Intrinsic protein disorder in oncogenic KRAS signaling.Neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans.
P2860
Q26751520-876B9BDE-8D8A-4D1C-82F8-3B115F7FD2EEQ26765438-0E25185C-6DDA-407E-9A01-61E7423973A0Q26766684-779341E4-4330-4751-9E70-62DD2EED6963Q27007866-13C59D8C-8F34-4BC4-9555-742E29079EC1Q28070394-60245937-962A-49FF-8414-7B5BEBCD06D5Q28260541-163CCA56-84E4-4596-8CBF-9F082D1ADD9BQ30844739-3AED6F9E-0466-409A-98CF-46ABF40AF4F2Q30851435-DF8049F9-A84C-425D-849E-CD3A0C85F971Q33683101-B6F58285-5617-44D0-98B2-CD462CD4E636Q33886255-A3B15012-A7EB-49D5-BC8A-5C437D337C14Q33887664-F5836CC5-4FFF-4833-90FD-4CA813550DEDQ36050056-FDF347B9-5170-4383-804D-5FBFC5579E1AQ36278636-E8320E39-A9BD-410D-AB1C-5954D3DFE3B8Q36369197-36CFA2E0-7609-4BD9-8FDB-DB0B2DE29DB2Q36416861-BA08A3A1-8C67-47B6-98C8-9F4294FA4367Q36665287-F332A252-3AA1-4A54-99A3-40287F01811BQ36669604-091C1270-A7C8-4456-8E27-7F49126F8DEFQ36909843-669D1DD7-ABF6-4D7F-B90B-DBDECA3A9763Q37113976-D51AB740-4C0A-4571-B53A-D7DFF19F7436Q37205817-4E7E93E6-23D1-439F-84A3-5520CE302E79Q37244633-BE88793D-45C5-44CD-95B3-2BD2C477641CQ37598923-B36EDB6D-B6AA-4907-9F74-A004CCA643ADQ37673912-8B709A84-BA08-4CD3-83AB-F1079697C54CQ38267209-738C72F7-B4E2-4D38-97E0-B7153BE21753Q38423050-D47C8C75-3876-466C-9F50-F58A3353780AQ38608107-3071C23E-00D8-433E-8908-A37F12C2BAC4Q38612793-8E1C1E18-9EB5-417C-AD5A-1CDE5EB3A6C0Q38722567-3886E6EE-9523-497A-A1DF-493B32114B84Q38723395-2E417160-B604-4E73-962C-697843407C64Q38731776-E9B405B6-0F48-4593-BBAF-9E1EFD398A65Q38740000-565A36E1-DC29-4CB2-A981-F2D91474C35DQ38809850-2F97D241-958E-4724-A6FE-06A4A2A0E230Q38891257-27EFF9AA-2CF1-4FEE-9F49-364E8878D666Q38898397-3097A9DB-928B-4B57-A584-99FFDECC6949Q38937455-852A1A51-F245-4396-BEC7-A722E0CB99DDQ39031613-0F5BAD4E-F92A-4A0D-89A6-DDE4B53619E4Q39163561-37CCA685-09CE-4FD2-8D2F-9F7B9125D96DQ39182842-B18E6551-0824-4F48-AD67-BBE819EB7221Q39361391-3FF76AFF-ED24-4E9E-B957-CD75C23260F6Q39707123-556617DD-157E-4649-A775-90EB11164C5A
P2860
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
@en
type
label
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
@en
prefLabel
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
@en
P2093
P2860
P1476
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
@en
P2093
Adrienne D Cox
Channing J Der
Mark R Philips
P2860
P304
P356
10.1158/1078-0432.CCR-14-3214
P407
P577
2015-04-01T00:00:00Z